Awards or Grants: National Institutes of Health (NIH) Academic Industrial Partnership (AIP) with an R1 grant award for “[a] new technique to make 68Ga-labeled pharmaceuticals widely available for clinical use.”
This recently completed National Institutes of Health (NIH) grant found a method to produce large quantities of gallium 68 from a cyclotron with solid targets so that this radiotracer can be produced within the institutional premises to enhance access to patients who need it for imaging. Aside from demonstrating higher production volume, a multitude of studies was conducted to demonstrate that the imaging quality of the cyclotron-produced Ga68 was not compromised.
Publications and Presentations:
Martinez, J., et al., MWMA2247 Cyclotron vs Generator-produced 68Ga PSMA: a single-institution, prospective clinical trial. In: ACNM Annual Meeting, 2022: ACNM.
Martinez J. et al., 68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study, Transl. Oncol.: 2022 Jan;15(1):101242.
Kalidindi T.M., et al., A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals, Eur. J. Nucl. Med. Mol. Imaging: 2021 Jul;48(8):2642-2651.
Osborne J.R., et al., Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer, l:. 2017 Dec;19(6):944-951. Erratum in Mol. Imaging Biol.: 2017 Jul 10.
Fung, E., et al., Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling, EJNMMI Research: 2016 6(1).
Osborne, J., et al., Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer, Mol. Imaging Biol., 19(6), pp.944-951.